Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: How much is enough?

Cancer

Volumn 113, Issue 4, 2008, Pages 710-716

  Decobert, Marc ^a   LaRue, Hélène ^a   Harel, François ^a   Meyer, François ^a   Fradet, Yves ^a   Lacombe, Louis ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Bacillus Calmette Gu rin (BCG); Bladder cancer; Immunotherapy; Maintenance BCG; Recurrence

Indexed keywords

BCG VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; BLADDER IRRITATION; BURNING SENSATION; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG INSTILLATION; DYSPNEA; FEMALE; FEVER; FOLLOW UP; HAZARD RATIO; HEMATURIA; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE METASTASIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TRANSURETHRAL RESECTION; TREATMENT DURATION;

EID: 50249087591     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23627     Document Type: Article

References (19)

1. McLaughlin JR, Dryer D, Mao Y, et al. Canadian Cancer Statistics 2006. Toronto, Canada: Canadian Cancer Society/ National Cancer Institute of Canada, 2006.
2. Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25:219-278.
3. Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992;19:499-508.
4. Rigaud J, Karam G, Braud G, Glemain P, Buzelin JM, Bouchot O. [T1 bladder tumors: value of a second endoscopic resection.] Prog Urol. 2002;12:27-30.
5. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006;97:1194-1198.
6. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996;155:1233-1238.
7. Altay B, Girgin C, Kefi A, Cikili N. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities? [In Process Citation.] Int Urol Nephrol. 2000;32:53-58.
8. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325:1205-1209.
9. Sylvester RJ, Van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-1970.
10. Lamm DL. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol. 1995;27(suppl 1):2-8.
11. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67:1216-1223.
12. Herr HW. Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol. 1991;145:40-43.
13. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell Carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-1129.
14. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803-1804.
15. Redmond C, Fisher B, Wieand HS. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep. 1983;67:519-526.
16. Collett D. Modelling Survival Data in Medical Research, 2nd ed. London: Chapman and Hall; 2003.
17. Andius P, Holmang S. Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int. 2004;93:980-984.
18. Van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44:429-434.
19. Saint F, Irani J, Patard JJ, et al. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology. 2001;57:883-888.